Neovascular Age-related Macular Degeneration Clinical Trials

31 recruitingLast updated: June 18, 2026

There are 31 actively recruiting neovascular age-related macular degeneration clinical trials across 38 countries. Studies span Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4. Top locations include Austin, Texas, United States, Sacramento, California, United States, West Columbia, South Carolina, United States. Updated daily from ClinicalTrials.gov.


Neovascular Age-related Macular Degeneration Trials at a Glance

31 actively recruiting trials for neovascular age-related macular degeneration are listed on ClinicalTrialsFinder across 6 cities in 38 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Austin, Sacramento, and West Columbia. Lead sponsors running neovascular age-related macular degeneration studies include Hoffmann-La Roche, Adverum Biotechnologies, Inc., and AbbVie.

Browse neovascular age-related macular degeneration trials by phase

Treatments under study

About Neovascular Age-related Macular Degeneration Clinical Trials

Looking for clinical trials for Neovascular Age-related Macular Degeneration? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neovascular Age-related Macular Degeneration trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neovascular Age-related Macular Degeneration clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 31 trials

Recruiting
Phase 4

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Neovascular Age-related Macular Degeneration
Genentech, Inc.188 enrolled51 locationsNCT04853251
Recruiting

Real-world Study of Aflibercept 8 mg in nAMD

Neovascular Age-Related Macular Degeneration (nAMD)
Peking University People's Hospital300 enrolled27 locationsNCT07640997
Recruiting
Phase 3

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular DegenerationnAMD
Amgen304 enrolled18 locationsNCT07614776
Recruiting

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Hoffmann-La Roche850 enrolled59 locationsNCT06680817
Recruiting
Phase 3

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular DegenerationnAMD
Hoffmann-La Roche68 enrolled16 locationsNCT05562947
Recruiting
Phase 3

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Neovascular Age-related Macular Degeneration
Hoffmann-La Roche1,000 enrolled165 locationsNCT03683251
Recruiting
Phase 2

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Adverum Biotechnologies, Inc.15 enrolled4 locationsNCT07630649
Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting
Phase 3

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration
AbbVie561 enrolled128 locationsNCT07007065
Recruiting
Phase 3

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Neovascular Age-related Macular Degeneration
Hoffmann-La Roche250 enrolled57 locationsNCT06847542
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled46 locationsNCT07482176
Recruiting
Phase 3

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Neovascular Age-related Macular Degeneration
Jaeb Center for Health Research600 enrolled65 locationsNCT05904028
Recruiting
Phase 1Phase 2

A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration
Intra-IMMUSG Pte Ltd15 enrolled1 locationNCT07547228
Recruiting
Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled94 locationsNCT07064759
Recruiting
Early Phase 1

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Neovascular Age-related Macular Degeneration
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine10 enrolled1 locationNCT07053358
Recruiting
Phase 3

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Innostellar Biotherapeutics Co.,Ltd332 enrolled31 locationsNCT07317934
Recruiting

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Hoffmann-La Roche1,000 enrolled41 locationsNCT06439576
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

Neovascular Age-related Macular Degeneration
Innovent Biologics Technology Limited (Shanghai R&D Center)800 enrolled1 locationNCT07275840
Recruiting
Phase 1Phase 2

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-Related Macular Degeneration (nAMD)
Alcon Research140 enrolled42 locationsNCT05769153
Recruiting
Phase 1Phase 2

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration
Sanofi66 enrolled18 locationsNCT06660667